KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to 40.49%.

  • Aurinia Pharmaceuticals' EBIT Margin rose 231500.0% to 40.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.34%, marking a year-over-year increase of 411700.0%. This contributed to the annual value of 1.99% for FY2024, which is 502500.0% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' EBIT Margin stood at 40.49%, which was up 231500.0% from 28.69% recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' EBIT Margin registered a high of 40.49% during Q3 2025, and its lowest value of 5529.87% during Q1 2021.
  • Its 5-year average for EBIT Margin is 382.87%, with a median of 38.97% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 1455704800bps in 2021, then crashed by -128000bps in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' EBIT Margin stood at 139.74% in 2021, then rose by 29bps to 98.82% in 2022, then skyrocketed by 33bps to 65.8% in 2023, then surged by 96bps to 2.79% in 2024, then surged by 1552bps to 40.49% in 2025.
  • Its EBIT Margin stands at 40.49% for Q3 2025, versus 28.69% for Q2 2025 and 34.97% for Q1 2025.